Back to search
FDAFDA · Food and drugs·Recall number D-0443-2024

Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactured by: Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-200-10

Published April 24, 2024 · Recall initiated: March 25, 2024

Summary

FDA records drug Class III recall D-0443-2024, published April 24, 2024 and initiated March 25, 2024. Recalling firm: Novitium Pharma LLC; Status: Terminated; Reported quantity: 1,003 bottles; Lot: Lot M23011A; Exp. 12/2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email if DIGOXIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
DIGOXIN
Manufacturer
Novitium Pharma LLC
Distributor
U.S. Nationwide
UPC
0370954201106
Lot
Lot M23011A; Exp. 12/2024
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Digoxin Tablets, USP 62.5 mcg (0.0625 mg), 100-count bottles, Rx Only, Manufactured by: Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-200-10 recalled?

Yes. FDA published recall D-0443-2024 on April 24, 2024. Reported hazard: Failed Impurities/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: DIGOXIN. UPC: 0370954201106.